McNulty PH, Tulli MA, Robertson BJ, Lendel V, Harach LA, Scott S, Boehmer JP. Effect of simulated postprandial hyperglycemia on coronary blood flow in cardiac transplant recipients. Am J Physiol Heart Circ Physiol 293: H103-H108, 2007. First published March 16, 2007; doi:10.1152/ajpheart.00779.2006.-Patients with diabetes mellitus exhibit postprandial hyperglycemia, systemic oxidative stress, impaired endothelium-dependent, nitric oxide (NO)-mediated coronary artery dilatation, and an increased incidence of coronary events. Whether hyperglycemia causally mediates these associations is unknown. To test the hypothesis that postprandial hyperglycemia acutely impairs coronary endothelial function in humans, we compared the ability of the endothelium-dependent vasodilator acetylcholine to increase conduit coronary diameter (the macrovascular response) and coronary blood flow velocity (the microvascular response) in 12 cardiac transplant recipients without diabetes before and after blood glucose was raised from 6.7 Ϯ 1.3 mmol/l (121 Ϯ 24 mg/dl) to 17.8 Ϯ 1.5 mmol/l (321 Ϯ 27 mg/dl) for 1 h. Hyperglycemia acutely doubled circulating levels of the oxidation product malondialdehyde, indicating systemic oxidative stress, but did not affect the ability of acetylcholine to dilate conduit coronary segments or accelerate coronary blood flow. We conclude that the oxidative stress associated with a single acute episode of hyperglycemia affects neither acetylcholine-mediated coronary endothelial NO release nor the subsequent bioavailability, metabolism, or action of NO within the coronary circulation of cardiac transplant recipients. These observations imply that the relationship among hyperglycemia, oxidative stress, and coronary endothelial dysfunction is presumably mediated by mechanisms operating over longer periods of time. diabetes mellitus; coronary artery; coronary endothelial dysfunction ONE OF THE EARLIEST ABNORMALITIES identified in both animal models of diabetes mellitus (29, 34) and humans with the disease (31, 32, 37) is impairment in the ability of the coronary endothelium to effect nitric oxide (NO)-mediated arterial dilatation. Several lines of evidence suggest this may be mediated by hyperglycemia. Hyperglycemia is the hallmark of diabetes and one of its earliest features. In vitro, hyperglycemia accelerates glucose consumption by endothelial cells resulting in cytosolic accumulation of diacylglycerol, activation of protein kinase C, and inhibition of endothelial NO synthase (eNOS) (12,43). Hyperglycemia also fuels the formation of reactive oxygen species (ROS) and of advanced glycosylation end products of endovascular proteins, both of which quench NO in vitro (5, 26). Perfusing the isolated rat heart with hyperglycemic solution for 1 h accelerates venous washout of nitrotyrosine (a byproduct of the reaction of ROS with NO) and increases coronary vascular resistance (9). Hyperglycemia may also stimulate the elaboration of substances [e.g., endothelin-1 (24, 35), tumor necrosis factor-␣ (11, 30)], which indirec...